CANF
Can-Fite BioPharma Ltd. AMEX Listed Nov 6, 2012$2.24
-0.21%
vs $2.24
Mkt Cap $2.9M
52w Low $2.16
0.8% of range
52w High $12.80
50d MA $3.08
200d MA $3.70
P/E (TTM)
—
EV/EBITDA
—
P/B
0.3x
Debt/Equity
0.0x
ROE
-175.8%
P/FCF
-0.2x
RSI (14)
18.50
ATR (14)
$0.14
Beta
-0.10
50d MA
$3.08
200d MA
$3.70
Avg Volume
737.8K
Can-Fite BioPharma Ltd., a clinical-stage biopharmaceutical company, develops small molecule therapeutic products for the treatment of cancer, liver inflammatory diseases, and erectile dysfunction. The company's lead drug candidate Piclidenoson, which has been completed Phase III clinical trial for the treatment of psoriasis; and Phase II clinical trial for the treatment of COVID-19. It also develops Namodenoson that is in Phase III clinical trial for the treatment of hepatocellular carcinoma, as well as in Phase IIb trial for the treatment of non-alcoholic steatohepatitis; and CF602, which is in pre-clinical trial for the treatment of erectile dysfunction. In addition, the company develops commercial predictive biomarker blood test kit for A3AR. Can-Fite BioPharma Ltd. has license and collaboration agreement with CMS Medical to develop, manufacture, and commercialize Piclidenoson and Namodenoson; and collaboration agreement with Univo Pharmaceuticals to identify and co-develop specific formulations of cannabis components for the treatment of cancer, inflammatory, autoimmune, and metabolic diseases. The company was formerly known as Can-Fite Technologies Ltd. and changed its name to Can-Fite BioPharma Ltd. in January 2001. Can-Fite BioPharma Ltd. was incorporated in 1994 and is headquartered in Petah Tikva, Israel.
10 Bareket Street · Petah Tikva, L3 4951778 · IL
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mar 26, 2026 | AMC | -27.00 | -5.97 | +77.9% | 3.29 | -0.6% | -4.6% | -4.1% | +3.0% | -0.3% | -0.6% | — |
| Aug 28, 2025 | AMC | -4.15 | -0.00 | +100.0% | 13.20 | -1.5% | -4.5% | +4.8% | +0.0% | -1.5% | +0.0% | — |
| Apr 14, 2025 | AMC | -0.10 | -0.10 | +0.0% | 26.00 | -2.3% | -3.1% | -2.4% | -2.4% | +3.3% | -5.6% | — |
| Mar 27, 2025 | AMC | -0.24 | -0.00 | +99.3% | 30.80 | -2.6% | -3.9% | +0.0% | -5.4% | +8.6% | -0.7% | — |
| Jan 2, 2025 | AMC | -0.27 | -0.27 | +0.0% | 35.80 | +0.6% | +1.1% | -3.3% | -5.1% | -5.4% | +0.6% | — |
| Dec 26, 2024 | AMC | -0.27 | -0.43 | -59.3% | 30.40 | -0.7% | +3.9% | -2.5% | +5.8% | +9.8% | +1.1% | — |
| Sep 26, 2024 | AMC | -0.36 | -0.40 | -11.1% | 41.00 | +0.0% | -1.5% | -0.5% | -3.0% | +0.5% | -0.5% | — |
| Aug 29, 2024 | AMC | -0.36 | -0.00 | +99.4% | 45.00 | +0.0% | -1.3% | +0.0% | +5.4% | -0.4% | -0.4% | — |
| Jul 4, 2024 | AMC | -0.40 | -0.00 | +99.5% | — | — | — | — | — | — | — | — |
| Jun 27, 2024 | AMC | -0.40 | -0.65 | -62.5% | 51.20 | +1.6% | +0.8% | +1.2% | -8.0% | +0.8% | +0.0% | — |
| Mar 28, 2024 | AMC | -0.27 | -6.20 | -2196.3% | 44.40 | +3.2% | +4.1% | -2.6% | +1.8% | +1.7% | +0.9% | — |
| Nov 30, 2023 | AMC | -0.44 | -5.29 | -1103.3% | 47.00 | -1.7% | +3.8% | -4.9% | -3.0% | +2.7% | -3.9% | — |
| Aug 31, 2023 | AMC | -10.80 | -6.99 | +35.2% | 58.80 | -2.0% | -2.4% | +5.2% | -7.0% | -0.4% | -0.7% | — |
| Jun 1, 2023 | AMC | -1.52 | -0.65 | +57.2% | 53.60 | +1.1% | +4.1% | +4.3% | -0.7% | -9.7% | +3.1% | — |
| Mar 30, 2023 | AMC | -0.91 | -22.20 | -2329.1% | 48.60 | -4.9% | -5.8% | -3.9% | -1.8% | -0.9% | +1.9% | — |
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| May 13 | D. Boral Capital | Upgrade | Hold → Buy | $7 | $3.39 | $3.44 | +1.5% | +7.4% | -4.1% | -3.7% | -3.0% | -0.3% |
| Dec 24 | D. Boral Capital | Downgrade | Buy → Hold | — | $4.81 | $4.00 | -16.8% | -24.9% | +18.6% | -19.9% | +7.0% | +9.0% |
| Dec 17 | D. Boral Capital | Maintains | Buy → Buy | — | $5.78 | $5.66 | -2.1% | -5.4% | -8.6% | +0.8% | -3.0% | -1.6% |
| Nov 18 | D. Boral Capital | Maintains | Buy → Buy | — | $7.20 | $11.00 | +52.8% | +5.6% | -13.2% | -6.1% | -6.5% | +13.8% |
| Sep 16 | D. Boral Capital | Maintains | Buy → Buy | — | $13.00 | $13.20 | +1.5% | +0.0% | +0.0% | +0.0% | +0.0% | -3.1% |
| Sep 2 | D. Boral Capital | Maintains | Buy → Buy | — | $12.60 | $12.80 | +1.6% | +4.8% | +0.0% | -1.5% | +0.0% | +1.5% |
| Jul 29 | D. Boral Capital | Maintains | Buy → Buy | — | $14.00 | $14.20 | +1.4% | +1.4% | -4.2% | -1.5% | -1.5% | +1.5% |
| Apr 15 | D. Boral Capital | Maintains | Buy → Buy | — | $26.00 | $25.40 | -2.3% | -3.1% | -2.4% | -2.4% | +3.3% | -5.6% |
| Mar 21 | D. Boral Capital | Maintains | Buy → Buy | — | $30.20 | $30.60 | +1.3% | +6.0% | +1.2% | -3.1% | -3.2% | +1.3% |
| Mar 20 | D. Boral Capital | Maintains | Buy → Buy | — | $32.60 | $32.20 | -1.2% | -7.4% | +6.0% | +1.2% | -3.1% | -3.2% |
| Mar 18 | D. Boral Capital | Maintains | Buy → Buy | — | $33.00 | $38.00 | +15.2% | +22.4% | -19.3% | -7.4% | +6.0% | +1.2% |
| Mar 3 | D. Boral Capital | Maintains | Buy → Buy | — | $35.20 | $35.60 | +1.1% | -2.3% | -5.8% | +0.0% | -1.2% | -1.2% |
| Feb 18 | D. Boral Capital | Maintains | Buy → Buy | — | $30.60 | $31.00 | +1.3% | +2.0% | +2.6% | +19.4% | -5.2% | -2.8% |
| Dec 31 | D. Boral Capital | Maintains | Buy → Buy | — | $30.80 | $31.40 | +1.9% | +5.8% | +9.8% | +1.1% | -3.3% | -5.1% |
| Dec 5 | D. Boral Capital | Maintains | Buy → Buy | — | $31.80 | $32.40 | +1.9% | -3.8% | +5.2% | -1.9% | +1.3% | +1.2% |
| Nov 12 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $42.20 | $42.00 | -0.5% | -1.4% | -0.5% | -3.9% | -1.5% | +2.0% |
| May 9 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $40.40 | $43.00 | +6.4% | +5.9% | -2.3% | +1.9% | +0.0% | -3.8% |
| Oct 24 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $38.40 | $40.20 | +4.7% | +1.6% | -2.1% | -0.5% | +1.6% | +4.1% |
| Jun 2 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $53.60 | $54.20 | +1.1% | +4.1% | +4.3% | -0.7% | -9.7% | +3.1% |
| Mar 13 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $49.60 | $54.60 | +10.1% | +1.6% | +0.0% | -8.7% | +2.2% | -3.4% |
| Sep 24 | H.C. Wainwright | Maintains | Buy → Buy | — | $492.00 | $490.00 | -0.4% | -6.9% | +0.4% | -8.3% | +0.0% | -2.4% |
| Mar 9 | Maxim Group | Downgrade | Buy → Hold | — | $5820.00 | $4800.00 | -17.5% | -19.6% | +0.6% | +1.3% | -3.8% | -0.7% |
| Aug 11 | Maxim Group | Maintains | Buy → Buy | — | $4590.00 | $5040.00 | +9.8% | +3.3% | +3.8% | -3.7% | +5.7% | -2.4% |
No insider trades available.
No recent filings available.
Institutional (13F) — Top 0
All ↗
No 13F holders found.
Mutual Funds / ETFs (N-PORT) — Top 7
All ↗
| # | Fund | Shares | Value | Period |
|---|---|---|---|---|
| 1 | Avantis Emerging Markets Equity ETF | 410,778 | $4M | Feb 2026 |
| 2 | Avantis Emerging Markets Value ETF | 37,412 | $347K | Feb 2026 |
| 3 | Avantis Emerging Markets Equity Fund | 24,030 | $223K | Feb 2026 |
| 4 | Avantis Emerging Markets ex-China Equity ETF | 7,289 | $68K | Feb 2026 |
| 5 | Avantis Emerging Markets Small Cap Equity ETF | 6,024 | $56K | Feb 2026 |
| 6 | Avantis Responsible Emerging Markets Equity ETF | 4,574 | $42K | Feb 2026 |
| 7 | Xtrackers Nifty 500 India ETF | 180 | $2K | Feb 2026 |
Valuation
Market Cap
$2.9M
Enterprise Value
-$6.7M
P/E (TTM)
—
Forward P/E
—
PEG Ratio
-0.00x
P/B
0.33x
P/S
7.24x
P/FCF
-0.20x
EV/EBITDA
—
Shares Out
824K
Financials (TTM)
Revenue
$405K
Net Income
-$9.8M
EBITDA
-$9.9M
Free Cash Flow
-$9.0M
Op Cash Flow
-$9.0M
EPS Basic
$-12.03
EPS Diluted
$-0.02
EPS Forward
$-0.83
Gross Margin
100.0%
Op Margin
—
Net Margin
—
Balance Sheet
Total Assets
$9.5M
Total Liab.
$3.9M
Total Equity
$5.6M
Cash
$8.5M
LT Debt
$0
Book Value/Sh
$6.79
Debt/Equity
0.01x
Current Ratio
3.46
Quick Ratio
3.46
Returns & Growth
ROE
-175.8%
ROA
-103.3%
ROIC
-146.6%
Rev Growth YoY
-39.4%
EPS Growth YoY
-1013.9%
Price Returns
2W
-4.7%
1M
-35.6%
3M
-26.8%
6M
-32.7%
12M
-82.8%
Technicals
52W High
$12.80
52W Low
$2.16
50d MA
$3.08
200d MA
$3.70
RSI (14)
18.50
ATR (14)
$0.14
Beta
-0.10
Avg Volume
738K
Dividends
Div Rate
$0.00
Div Yield
—
Frequency
—
Ex-Div Date
—
Analyst Price Targets
Consensus
$145.00
High
$200.00
Low
$90.00
Median
$145.00
Data updated apr 26, 2026 10:04am
· Source: financialmodelingprep.com